These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7055013)

  • 1. Some aspects of the dopaminergic action of ergot derivatives and their role in the treatment of migraine.
    Horowski R
    Adv Neurol; 1982; 33():325-34. PubMed ID: 7055013
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects on arterial receptors of ergot derivatives used in migraine.
    Müller-Schweinitzer E; Fanchamps A
    Adv Neurol; 1982; 33():343-56. PubMed ID: 6275676
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of ergot derivatives on prolactin secretion in rats. Mechanisms of action and clinical implications.
    Horowski R
    Cephalalgia; 1983 Aug; 3 Suppl 1():131-8. PubMed ID: 6616595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of antiserotonergic agents on the action of dopaminergic drugs.
    Mogilnicka E; Scheel-Krüger J; Klimek V; Golembiowska-Nikitin K
    Pol J Pharmacol Pharm; 1977; 29(1):31-8. PubMed ID: 140371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metergoline and other peripheral serotonin antagonists inhibit prolactin secretion through mechanisms unrelated to serotonin.
    Lamberts SW; MacLeod RM
    Proc Soc Exp Biol Med; 1979 Oct; 162(1):75-9. PubMed ID: 504241
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacology of ergot alkaloids in clinical use.
    Berde B
    Med J Aust; 1978 Nov; 2(3 Suppl):3-13. PubMed ID: 370528
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women.
    Bohnet HG; Kato K; De Moll H
    Obstet Gynecol; 1988 Jan; 71(1):53-5. PubMed ID: 3336541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep.
    Clarenbach P; Del Pozo E; Brownell J; Heredia E; Spiegel R; Cramer H
    Brain Res; 1980 Dec; 202(2):357-63. PubMed ID: 7437907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action of dopamine receptor agonists and antagonists, and a serotonin antagonist on prolactin release from isolated rat pituitary cell columns [proceedings].
    Delitala G; Stubbs WA; Yeo T; Jones A; Thorner MO; Besser GM
    J Endocrinol; 1979 May; 81(2):121P. PubMed ID: 458305
    [No Abstract]   [Full Text] [Related]  

  • 10. Interaction of dopaminergic ergot derivatives with cyclic nucleotide system.
    Spano PF; Saiani L; Memo M; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():95-102. PubMed ID: 6249093
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Acta Endocrinol Suppl (Copenh); 1978; 216():27-56. PubMed ID: 347864
    [No Abstract]   [Full Text] [Related]  

  • 12. [Role of the prostaglandin system in the monoaminergic control of prolactin release in the rat].
    Costa G; Trovato A; Abate F; De Pasquale R; Galati EM
    Boll Soc Ital Biol Sper; 1979 Aug; 55(15):1492-7. PubMed ID: 261818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of dopaminergic and antiserotoninergic drugs in the control of prolactin and LH release in normal women.
    Pontiroli AE; Alberetto M; Pellicciotta G; De Castro e Silva E; De Pasqua A; Girardi AM; Pozza G
    Acta Endocrinol (Copenh); 1980 Mar; 93(3):271-6. PubMed ID: 7376792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic mechanisms of antimigraine drugs.
    Fozard JR
    Adv Neurol; 1982; 33():295-307. PubMed ID: 7034488
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-induced changes of brain serotoninergic tone and insulin-induced growth hormone release in the dog.
    Locatelli V; Panerai AE; Cocchi D; Gil-Ad I; Mantegazza P; Secchi C; Müller EE
    Neuroendocrinology; 1978; 25(2):84-104. PubMed ID: 652121
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion.
    Ferrari C; Caldara R; Romussi M; Rampini P; Telloli P; Zaatar S; Curtarelli G
    Neuroendocrinology; 1978; 25(6):319-28. PubMed ID: 662080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain.
    Rosenfeld MR; Makman MH
    J Pharmacol Exp Ther; 1981 Mar; 216(3):526-31. PubMed ID: 7205633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of neurotransmitter receptor binding by ergot derivatives.
    Hruska RE; Silbergeld EK
    J Neurosci Res; 1981; 6(1):1-11. PubMed ID: 6111611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New central dopamine agonists.
    Borsy J
    Pol J Pharmacol Pharm; 1985; 37(3):227-36. PubMed ID: 2999737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin antagonist-induced lowering of prolactin secretion does not affect the pattern of pulsatile secretion of follicle-stimulating hormone and luteinizing hormone in the bitch.
    Beijerink NJ; Kooistra HS; Dieleman SJ; Okkens AC
    Reproduction; 2004 Aug; 128(2):181-8. PubMed ID: 15280557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.